STLN on Nasdaq
Starling Oncology, Inc.
American Offices and Clinics of Doctors of Medicine services company. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with One Medical, LifeMD, Inc. or SBC Medical Group Holdings Inc, or pick any stock.
- TickerSTLN on Nasdaq1
- IndustryServices-Offices & Clinics of Doctors of Medicine1
- HeadquartersCerritos, California1
- Incorporated inDE2
- Business address18000 Studebaker Rd, Suite 800, Cerritos, Ca 907032
- Filer categoryAccelerated filer, Smaller reporting company2
- Legal formCorporation
See how the biggest companies compare on our leaderboards
Formed in 2007, the business of what is now The Oncology Institute, Inc. ("TOI", the "Company", "we", or "our) and its affiliated professional corporations was created initially as a collection of community oncology practices in southern California, and has evolved to be a national leader in the pursuit of reducing the ever-rising cost of oncology care, while embracing clinical best practices, state-of-the-art technology, and compassionate treatment of patients.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Health Care, Specialty Pharmacy brought in 54% of the revenue Starling Oncology, Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Health Care, Specialty Pharmacy | $179.9M | $269.2M |
| Fee For Service | $136.2M | $148.5M |
| Capitated Revenue | $68.7M | $80.5M |
| Clinical Research Trials And Other Revenue | $8.6M | $4.6M |
Business segments
Specialty pharmacy, brought in 54% of the revenue Starling Oncology, Inc. broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2024 | 2025 |
|---|---|---|
| Specialty pharmacy, | $179.9M | $269.2M |
| Patient Services, | $204.9M | $229.0M |
| Clinical Trials And Other, | $8.6M | $4.6M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Selling, general and admin21¢$105.6M
- Other costs79¢$397.0M
- Income tax0¢$131.0K
Out of $502.7M in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total operating revenue | $502.7M | $393.4M |
| Selling, general and administrative expense | $105.6M | $107.8M |
| Depreciation and amortization | $6.9M | $6.3M |
| Total operating expenses | $538.8M | $453.5M |
| Loss from operations | -$36.1M | -$60.1M |
| Interest expense, net | $11.3M | $7.5M |
| Change in fair value of derivative warrant liabilities | $247.0K | -$619.0K |
| Change in fair value of conversion option derivative liabilities | $12.2M | -$2.7M |
| Other, net | $925.0K | $365.0K |
| Total other non-operating expense | $24.7M | $4.5M |
| Loss before provision for income taxes | -$60.7M | -$64.7M |
| Income tax benefit | $131.0K | $0 |
| Net loss | -$60.6M | -$64.7M |
| Net loss attributable to common stockholders, basic | -$50.3M | -$53.0M |
| Net loss attributable to common stockholders, diluted | -$50.3M | -$53.0M |
| Weighted-average number of shares outstanding, basic (in shares) | 92.4M shares | 75.0M shares |
| Weighted-average number of shares outstanding, diluted (in shares) | 92.4M shares | 75.0M shares |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -$0.54 | -$0.71 |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -$0.54 | -$0.71 |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2021-10-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $33.6M | $49.7M | $33.5M | |
| Accounts receivable, net | $59.0M | $48.3M | ||
| Other receivables | $322.0K | $346.0K | ||
| Inventories | $16.9M | $10.0M | ||
| Prepaid expenses and other current assets | $3.0M | $4.0M | ||
| Total current assets | $112.7M | $112.4M | ||
| Property and equipment, net | $10.7M | $11.9M | ||
| Operating right of use assets | $22.4M | $25.8M | ||
| Intangible assets, net | $11.0M | $14.8M | ||
| Goodwill | $7.2M | $7.2M | ||
| Other assets | $606.0K | $589.0K | ||
| Total assets | $164.7M | $172.7M | ||
| Accounts payable | $43.2M | $24.3M | ||
| Current portion of operating lease liabilities | $7.2M | $6.8M | ||
| Accrued expenses and other current liabilities | $20.6M | $21.1M | ||
| Total current liabilities | $71.0M | $52.2M | ||
| Operating lease liabilities | $19.1M | $23.2M | ||
| Derivative warrant liabilities | $264.0K | $17.0K | ||
| Conversion option derivative liabilities | $12.6M | $385.0K | ||
| Long-term debt, net of unamortized debt issuance costs | $77.4M | $93.1M | ||
| Other non-current liabilities | $28.0K | $125.0K | ||
| Deferred income taxes liability | $0 | $32.0K | ||
| Commitments and contingencies (Note 15) | $0 | $0 | ||
| Common Stock, 0.0001 par value, authorized 500,000,000 shares; 100,596,918 shares issued and 98,863,144 shares outstanding at December 31, 2025 and 77,470,886 shares issued and 75,737,112 shares outstanding at December 31, 2024 | $10.0K | $8.0K | ||
| Series A Convertible Preferred Stock, 0.0001 par value, authorized 10,000,000 shares; 193,507 and 165,045 shares issued and outstanding at December 31, 2025 and 2024, respectively | $0 | $0 | ||
| Additional paid-in capital | $256.7M | $215.4M | ||
| Treasury Stock at cost, 1,733,774 shares at December 31, 2025 and 2024 | -$1.0M | -$1.0M | ||
| Accumulated deficit | -$271.4M | -$210.8M | ||
| Total stockholders equity (deficit) | -$15.7M | $3.6M | $57.0M | |
| Total liabilities and stockholders equity (deficit) | $164.7M | $172.7M | ||
| Common shares, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 500.0M shares | 500.0M shares | ||
| Common stock, shares issued (in shares) | 100.6M shares | 77.5M shares | ||
| Common stock, shares outstanding (in shares) | 98.9M shares | 75.7M shares | ||
| Series A preferred shares, par value (in dollars per share) | $0.00 | $0.00 | $0.00 | |
| Series A preferred shares, authorized (in shares) | 10.0M shares | 10.0M shares | 10.0M shares | |
| Series A preferred shares, shares issued (in shares) | 193.5K shares | 165.0K shares | ||
| Series A preferred shares, outstanding (in shares) | 193.5K shares | 165.0K shares | ||
| Treasury stock (in shares) | 1.7M shares | 1.7M shares | ||
| Total liabilities | $180.4M | $169.1M |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2021-10-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $33.6M | $49.7M | $33.5M | |
| Accounts receivable, net | $59.0M | $48.3M | ||
| Other receivables | $322.0K | $346.0K | ||
| Inventories | $16.9M | $10.0M | ||
| Prepaid expenses and other current assets | $3.0M | $4.0M | ||
| Total current assets | $112.7M | $112.4M | ||
| Property and equipment, net | $10.7M | $11.9M | ||
| Operating right of use assets | $22.4M | $25.8M | ||
| Intangible assets, net | $11.0M | $14.8M | ||
| Goodwill | $7.2M | $7.2M | ||
| Other assets | $606.0K | $589.0K | ||
| Total assets | $164.7M | $172.7M | ||
| Accounts payable | $43.2M | $24.3M | ||
| Current portion of operating lease liabilities | $7.2M | $6.8M | ||
| Accrued expenses and other current liabilities | $20.6M | $21.1M | ||
| Total current liabilities | $71.0M | $52.2M | ||
| Operating lease liabilities | $19.1M | $23.2M | ||
| Derivative warrant liabilities | $264.0K | $17.0K | ||
| Conversion option derivative liabilities | $12.6M | $385.0K | ||
| Long-term debt, net of unamortized debt issuance costs | $77.4M | $93.1M | ||
| Other non-current liabilities | $28.0K | $125.0K | ||
| Deferred income taxes liability | $0 | $32.0K | ||
| Commitments and contingencies (Note 15) | $0 | $0 | ||
| Common Stock, 0.0001 par value, authorized 500,000,000 shares; 100,596,918 shares issued and 98,863,144 shares outstanding at December 31, 2025 and 77,470,886 shares issued and 75,737,112 shares outstanding at December 31, 2024 | $10.0K | $8.0K | ||
| Series A Convertible Preferred Stock, 0.0001 par value, authorized 10,000,000 shares; 193,507 and 165,045 shares issued and outstanding at December 31, 2025 and 2024, respectively | $0 | $0 | ||
| Additional paid-in capital | $256.7M | $215.4M | ||
| Treasury Stock at cost, 1,733,774 shares at December 31, 2025 and 2024 | -$1.0M | -$1.0M | ||
| Accumulated deficit | -$271.4M | -$210.8M | ||
| Total stockholders equity (deficit) | -$15.7M | $3.6M | $57.0M | |
| Total liabilities and stockholders equity (deficit) | $164.7M | $172.7M | ||
| Common shares, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 500.0M shares | 500.0M shares | ||
| Common stock, shares issued (in shares) | 100.6M shares | 77.5M shares | ||
| Common stock, shares outstanding (in shares) | 98.9M shares | 75.7M shares | ||
| Series A preferred shares, par value (in dollars per share) | $0.00 | $0.00 | $0.00 | |
| Series A preferred shares, authorized (in shares) | 10.0M shares | 10.0M shares | 10.0M shares | |
| Series A preferred shares, shares issued (in shares) | 193.5K shares | 165.0K shares | ||
| Series A preferred shares, outstanding (in shares) | 193.5K shares | 165.0K shares | ||
| Treasury stock (in shares) | 1.7M shares | 1.7M shares | ||
| Total liabilities | $180.4M | $169.1M |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$60.6M | -$64.7M |
| Depreciation and amortization | $6.9M | $6.3M |
| Amortization of debt issuance costs and debt discount | $8.4M | $6.3M |
| Write-off of assets from clinical trials segment | $2.4M | |
| Share-based compensation | $4.6M | $11.2M |
| Change in fair value of liability classified warrants | $247.0K | -$619.0K |
| Change in fair value of liability classified conversion option derivatives | $12.2M | -$2.7M |
| Unrealized (gain) loss on investments | $0 | -$133.0K |
| Accretion of discount on investment securities | $0 | -$500.0K |
| Deferred taxes | -$32.0K | $0 |
| Loss on disposal of property and equipment | $0 | $271.0K |
| Accounts receivable | -$12.3M | -$6.0M |
| Inventories | -$6.8M | $3.6M |
| Other receivables | -$274.0K | $205.0K |
| Prepaid expenses | $2.0M | $1.2M |
| Other assets | -$17.0K | -$28.0K |
| Accrued expenses and other current liabilities | -$448.0K | $9.5M |
| Accounts payable | $19.6M | $9.2M |
| Change in operating leases | -$452.0K | $559.0K |
| Other non-current liabilities | -$11.0K | -$203.0K |
| Net cash and cash equivalents used in operating activities | -$24.6M | -$26.5M |
| Purchases of property and equipment | -$3.2M | -$3.8M |
| Proceeds from asset disposition | $126.0K | $0 |
| Sales of marketable securities/investments | $0 | $50.0M |
| Net cash and cash equivalents provided by (used in) investing activities | -$3.1M | $46.2M |
| Proceeds from private placement, net of offering costs | $15.4M | $0 |
| Proceeds from at-the-market offering, net of offering costs | $13.8M | $0 |
| Proceeds from employee stock purchase plan | $151.0K | $0 |
| Payments made for financing of insurance payments | -$991.0K | -$1.2M |
| Payment of deferred consideration liability for acquisition | -$50.0K | -$2.4M |
| Principal payments on long-term debt | -$20.0M | $0 |
| Principal payments on financing leases | -$37.0K | -$39.0K |
| Common stock issued for warrants exercised | $517.0K | $0 |
| Common stock issued for options exercised | $2.8M | $75.0K |
| Net cash and cash equivalents provided by (used in) financing activities | $11.6M | -$3.5M |
| Net (decrease) increase in cash and cash equivalents | -$16.1M | $16.2M |
| Interest | $3.9M | $4.5M |
| Principal exchange of convertible note for preferred stock | $4.1M | $0 |
| Right-of-use assets in connection with operation lease modifications | $1.6M | $1.4M |
| Financed insurance premiums | $794.0K | $844.0K |
| Purchases of property and equipment included in accounts payable | $441.0K | $680.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Starling Oncology, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
2025
- Chief executive officerDaniel Virnich Nov 16, 2023 to now13
- Chief executive officerBrad Hively Nov 16, 2021 to Mar 21, 202314
- ChairRichard A. Barasch Mar 10, 2020 to Mar 10, 202015
- PresidentDaniel Virnich Mar 23, 2022 to Mar 21, 202316
- Chief financial officerMihir Shah May 19, 2022 to May 23, 202417
- Chief financial officerScott Dalgleish Nov 16, 2021 to Mar 29, 202218
- Chief financial officerChris Wolfe Mar 10, 2020 to Mar 10, 202019
- Chief operating officerJeremy Castle Sep 7, 2023 to now20
- Chief operating officerDaniel Virnich Nov 16, 2021 to Nov 16, 202121
Board members and other officers (21)
- Chief Clinical OfficerJeffrey Langsam May 23, 2025 to now22
- Chief Administrative OfficerKristin England Jul 22, 2025 to now23
- Chief Operations OfficerJeremy Castle Oct 8, 2024 to Oct 8, 202424
- Chief Accounting OfficerDiona Simoneit Nov 17, 2022 to Nov 22, 202225
- Chief Medical OfficerYale Podnos Nov 16, 2021 to now26
- Board memberMark Stolper Jan 12, 2026 to now27
- Board memberKimberly Jo Tzoumakas Mar 20, 2026 to now28
- Board memberGrowth I. L.p. M33 Mar 28, 2025 to now29
- Board memberGabriel Ling Sep 23, 2022 to now30
- Board memberMark L. Pacala Sep 23, 2022 to now31
- Board memberAnne McGeorge Nov 16, 2021 to now32
- Board memberBrad Hively Nov 16, 2021 to now14
- Board memberKaren Marie Johnson Nov 16, 2021 to now33
- Board memberMaeve O'Meara Nov 16, 2021 to Dec 28, 202334
- Board memberRavi Yang Sarin Nov 16, 2021 to Mar 21, 202335
- Board memberRichard A. Barasch Nov 16, 2021 to now36
- Board memberJames E. Flynn Mar 10, 2020 to Mar 17, 202037
- Board memberMgmt L.p. Deerfield Iv. Mar 10, 2020 to Mar 17, 202037
- Board memberMohit Kaushal Mar 10, 2020 to now38
- Board memberLawrence Atinsky Mar 11, 2020 to Mar 11, 202039
- Board memberJennifer L. Carter Mar 12, 2020 to Mar 12, 202040
Named in SEC Form D filings
People the company listed in its private-offering notices.
Former names
Timeline
Filings
497 filings to the SEC since October 2021: 8 annual reports, 17 quarterly reports, 77 major events, 257 insider forms, 33 large holders, 2 private raises, 103 other. The latest 20:
- Sep 2, 20268-K EDGAR
- Aug 24, 20264 EDGAR
- Aug 21, 2026144 EDGAR
- Aug 21, 20268-K EDGAR
- Aug 17, 20264 OWNERSHIP DOCUMENT EDGAR
- Aug 6, 202610-Q EDGAR
- Aug 6, 20268-K EDGAR
- Aug 3, 20268-K EDGAR
- Jul 29, 20264 EDGAR
- Jul 29, 20264 EDGAR
- Jul 29, 20264 EDGAR
- Jul 29, 20264 EDGAR
- Jul 29, 20264 EDGAR
- Jul 29, 20264 EDGAR
- Jul 29, 20264 EDGAR
- Jul 22, 20264 OWNERSHIP DOCUMENT EDGAR
- Jul 16, 20264 EDGAR
- Jul 14, 2026144 EDGAR
- Jul 13, 20264 OWNERSHIP DOCUMENT EDGAR
- Jul 9, 20264 EDGAR
The 497 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
124 open-market trades by officers, directors and large owners since October 2021: 33 buys and 91 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 21, 2026 | Hively BradDirector | Sale | 298,853 | $6.51 | $1.9M | Form 4 |
| Aug 14, 2026 | Chernett Jorey10% owner | Buy | 12,000 | $6.54 | $78.5K | Form 4 |
| Jul 21, 2026 | Chernett Jorey10% owner | Buy | 18,000 | $5.27 | $94.9K | Form 4 |
| Jul 14, 2026 | Podnos YaleChief Medical Officer | Sale | 23,452 | $6.41 | $150.4K | Form 4 |
| Jul 10, 2026 | Chernett Jorey10% owner | Buy | 15,000 | $5.85 | $87.8K | Form 4 |
| Jun 23, 2026 | Chernett Jorey10% owner | Buy | 18,000 | $5.02 | $90.4K | Form 4 |
| Jun 8, 2026 | Podnos YaleChief Medical Officer | Sale | 23,451 | $5.38 | $126.2K | Form 4 |
| Jun 4, 2026 | Chernett Jorey10% owner | Buy | 12,000 | $4.75 | $57.0K | Form 4 |
| May 20, 2026 | Chernett Jorey10% owner | Buy | 33,500 | $4.07 | $136.3K | Form 4 |
| May 19, 2026 | Chernett Jorey10% owner | Buy | 5,000 | $4.05 | $20.2K | Form 4 |
| May 19, 2026 | Chernett Jorey10% owner | Buy | 30,000 | $4.09 | $122.7K | Form 4 |
| Apr 16, 2026 | Kaushal MohitDirector | Sale | 38,433 | $3.50 | $134.5K | Form 4 |
| Apr 14, 2026 | Kaushal MohitDirector | Sale | 57,286 | $3.50 | $200.5K | Form 4 |
| Apr 9, 2026 | Chernett Jorey10% owner | Buy | 20,000 | $3.10 | $62.0K | Form 4 |
| Mar 27, 2026 | Chernett Jorey10% owner | Buy | 27,429 | $2.96 | $81.2K | Form 4 |
| Mar 26, 2026 | Chernett Jorey10% owner | Buy | 50,000 | $3.15 | $157.5K | Form 4 |
| Mar 24, 2026 | Chernett Jorey10% owner | Buy | 125,000 | $3.11 | $388.8K | Form 4 |
| Mar 20, 2026 | Chernett Jorey10% owner | Buy | 25,000 | $3.35 | $83.8K | Form 4 |
| Mar 17, 2026 | Chernett Jorey10% owner | Buy | 75,000 | $3.42 | $256.5K | Form 4 |
| Mar 16, 2026 | Chernett Jorey10% owner | Buy | 60,985 | $3.29 | $200.6K | Form 4 |
All 124 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- M33 Growth I L.P.SCHEDULE 13D/A, 7 filings Nov 22, 2021 to May 15, 202643
- Jorey ChernettSCHEDULE 13G/A, 2 filings Jan 15, 2026 to Mar 16, 202644
- FOG Ventures Investments, LLCSCHEDULE 13G/A, 2 filings Nov 24, 2021 to Jun 24, 202545
- Ravi Yang SarinSCHEDULE 13D/A, 2 filings Nov 22, 2021 to Apr 23, 202546
- FMR LLCSCHEDULE 13G/A, 4 filings Dec 10, 2021 to Dec 6, 202447
- Havencrest Healthcare Partners, L.P.SC 13D/A, 6 filings Nov 22, 2021 to Aug 20, 202448
- Richy AgajanianSC 13G/A, 3 filings Nov 26, 2021 to Apr 3, 202349
- CITADEL ADVISORS LLCSC 13G/A, 1 filing Feb 14, 202250
- INTEGRATED CORE STRATEGIES (US) LLCSC 13G/A, 1 filing Feb 14, 202251
- Park West Asset Management LLCSC 13G/A, 1 filing Feb 14, 202252
- DAVIDSON KEMPNER PARTNERSSC 13G/A, 1 filing Feb 10, 202253
- James E. FlynnSC 13D/A, 1 filing Nov 19, 202154
- Lawrence FeisSC 13G/A, 2 filings Nov 9, 2021 to Nov 15, 202155
Money raised
Private offerings the company reported to the SEC on Form D.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 4,749,030 | $25.8M | 0.0% | +333,163 |
| Deerfield Management Company, L.P. | 3,360,052 | $18.2M | 0.2% | No change |
| Vanguard Capital Management LLC | 3,265,531 | $17.7M | 0.0% | −211,250 |
| Josh Arnold Investment Consultant, LLC | 2,464,359 | $13.4M | 8.4% | No change |
| Geode Capital Management, LLC | 1,899,998 | $10.3M | 0.0% | +142,151 |
| Goldman Sachs Group Inc | 1,735,337 | $9.4M | 0.0% | +383,438 |
| Wexford Capital LP | 1,711,323 | $9.3M | 1.3% | No change |
| State Street Corp | 1,552,917 | $8.4M | 0.0% | +91,463 |
| Nuveen, LLC | 1,408,720 | $7.6M | 0.0% | +1,313,456 |
| Renaissance Technologies LLC | 1,365,913 | $7.4M | 0.0% | +463,104 |
| CenterBook Partners LP | 1,241,660 | $6.7M | 0.3% | −326,763 |
| Marshall Wace, Llp | 1,222,498 | $6.6M | 0.0% | +880,233 |
| Vanguard Portfolio Management LLC | 1,007,037 | $5.5M | 0.0% | +144,198 |
| Citadel Advisors LLC | 894,101 | $4.9M | 0.0% | +285,834 |
| Jane Street Group, LLC | 852,163 | $4.6M | 0.0% | +427,269 |
| BRC Group Holdings, Inc. | 742,593 | $4.0M | 0.9% | −187,141 |
| Arrowstreet Capital, Limited Partnership | 710,888 | $3.9M | 0.0% | +291,465 |
| Two Sigma Investments, LP | 668,839 | $3.6M | 0.0% | +361,085 |
| Northern Trust Corp | 591,534 | $3.2M | 0.0% | +33,079 |
| Vanguard Fiduciary Trust Co | 502,049 | $2.7M | 0.0% | +18,989 |
| FourWorld Capital Management LLC | 499,196 | $2.7M | 3.1% | No change |
| Manatuck Hill Partners, LLC | 450,000 | $2.4M | 0.8% | New |
| Walleye Capital LLC | 445,832 | $2.4M | 0.0% | New |
| Inspire Investing, LLC | 424,008 | $2.3M | 0.1% | New |
| Jpmorgan Chase & Co | 409,348 | $2.3M | 0.0% | +39,171 |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14SEC EDGARBrad Hively, Chief executive officer
- 15SEC EDGARRichard A. Barasch, Chair
- 16SEC EDGARDaniel Virnich, President
- 17SEC EDGARMihir Shah, Chief financial officer
- 18
- 19SEC EDGARChris Wolfe, Chief financial officer
- 20
- 21
- 22
- 23
- 24
- 25
- 26SEC EDGARYale Podnos, Chief Medical Officer
- 27SEC EDGARMark Stolper, Board member
- 28SEC EDGARKimberly Jo Tzoumakas, Board member
- 29SEC EDGARGrowth I. L.p. M33, Board member
- 30SEC EDGARGabriel Ling, Board member
- 31SEC EDGARMark L. Pacala, Board member
- 32SEC EDGARAnne McGeorge, Board member
- 33SEC EDGARKaren Marie Johnson, Board member
- 34SEC EDGARMaeve O'Meara, Board member
- 35SEC EDGARRavi Yang Sarin, Board member
- 36SEC EDGARRichard A. Barasch, Board member
- 37SEC EDGARJames E. Flynn, Board member
- 38SEC EDGARMohit Kaushal, Board member
- 39SEC EDGARLawrence Atinsky, Board member
- 40SEC EDGARJennifer L. Carter, Board member
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55